Evidence map›Paper›PMID 22015269›Full record

ArticlePeptides2011

Design and synthesis of biologically active peptides: a 'tail' of amino acids can modulate activity of synthetic cyclic peptides.

Alberto Bryan, Leroy Joseph, James A Bennett, Herbert I Jacobson, Thomas T Andersen

Abstract read
In one paragraph

Article in Peptides, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alberto BryanCenter for Cardiovascular Science, Albany Medical College, Albany, NY 12208, USA.
Leroy Joseph
James A Bennett
Herbert I Jacobson
Thomas T Andersen
Albany Medical Center Hospital · US

Funding

MARC/Biomedical Research and Training Program at the University of ArizonaT34GM008718 · NIGMS · UNIVERSITY OF ARIZONA · PI MIRANDA, KATRINA M. · 1999 to 2021
$8.6M
Synthetic Peptides from AFP Prevent Breast CancerR01CA102540 · NCI · ALBANY MEDICAL COLLEGE · PI ANDERSEN, THOMAS T · 2003 to 2006
$1.2M
CROSS TRAINING OF UNDERGRADUATE STUDENTSR25GM062460 · NIGMS · ALBANY MEDICAL COLLEGE · PI ANDERSEN, THOMAS T · 2001 to 2008
$436k
NCI NIH HHS 5 R01 CA102540NCI NIH HHS R01 CA102540NIGMS NIH HHS 5 R25 GM 062460NIGMS NIH HHS R25 GM062460NIGMS NIH HHS T34 GM008718NIGMS NIH HHS T34GM 008718
6 · The paper itself

Abstract

In earlier work, we synthesized a cyclic 9-amino acid peptide (AFPep, cyclo[EKTOVNOGN]) and showed it to be useful for prevention and therapy of breast cancer. In an effort to explore the structure-function relationships of AFPep, we have designed analogs that bear a short 'tail' (one or two amino acids) attached to the cyclic peptide distal to its pharmacophore. Analogs that bore a tail of either one or two amino acids, either of which had a hydrophilic moiety in the side chain (e.g., cyclo[EKTOVNOGN]FS) exhibited greatly diminished biological activity (inhibition of estrogen-stimulated uterine growth) relative to AFPep. Analogs that bore a tail of either one or two amino acids which had hydrophobic (aliphatic or aromatic) side chains (e.g., cyclo[EKTOVNOGN]FI) retained (or had enhanced) growth inhibition activity. Combining in the same biological assay a hydrophilic-tailed analog with either AFPep or a hydrophobic-tailed analog resulted in decreased activity relative to that for AFPep or for the hydrophobic-tailed analog alone, suggesting that hydrophilic-tailed analogs are binding to a biologically active receptor. An analog with a disrupted pharmacophore (cyclo[EKTOVGOGN]) exhibited little or no growth inhibition activity. An analog with a hydrophilic tail and a disrupted pharmacophore (cyclo[EKTOVGOGN]FS) exhibited no growth inhibition activity of its own and did not affect the activity of a hydrophobic-tailed analog, but enhanced the growth inhibition activity of AFPep. These results are discussed in the context of a two-receptor model for binding of AFPep and ring-and-tail analogs. We suggest that tails on cyclic peptides may comprise a useful method to enhance diversity of peptide design and specificity of ligand-receptor interactions.

Indexed as

alpha-FetoproteinsAmino AcidsAmino Acid SequenceAnimalsAntineoplastic AgentsBinding SitesEstradiolFemaleHydrophobic and Hydrophilic InteractionsMiceModels, MolecularPeptides, CyclicProtein ConformationReceptors, Cell SurfaceSolid-Phase Synthesis TechniquesStructure-Activity Relationshipalpha-FetoproteinsAmino AcidsAntineoplastic AgentsEstradiolPeptides, CyclicReceptors, Cell Surface

Identifiers

PMID22015269
PMCPMC3230782
OpenAlexW2019852463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.